Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Pipeline Review, H2 2016

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Pipeline Review, H2 2016


  • Products Id :- GMDHC0702TDB
  • |
  • Pages: 62
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Pipeline Review, H2 2016', provides in depth analysis on Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted pipeline therapeutics.

The report provides comprehensive information on the Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)

The report reviews Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics and enlists all their major and minor projects

The report assesses Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) Overview 7

Therapeutics Development 8

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Products under Development by Stage of Development 8

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Products under Development by Therapy Area 9

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Products under Development by Indication 10

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Products under Development by Companies 14

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Products under Development by Universities/Institutes 16

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Companies Involved in Therapeutics Development 24

AstraZeneca Plc 24

Cantex Pharmaceuticals Inc 25

Chiesi Farmaceutici SpA 26

Kyorin Pharmaceutical Co Ltd 27

Polyphor Ltd 28

Proteo Inc 29

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Drug Profiles 30

ANV-201-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

AZD-9668-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

brevenal-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

dociparstat sodium-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

KRP-109-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

POL-6014-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Polysaccharides to Inhibit P-Selectin and HLE for Age-Related Macular Degeneration-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecule 1 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecule 2 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecule to Inhibit Neutrophil Elastase for Respiratory Diseases-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

tiprelestat-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Dormant Projects 46

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Discontinued Products 50

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)-Featured News & Press Releases 51

Jun 06, 2016: Proteo receives US$ 1 million grant for a new Elafin drug formulation 51

Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia 51

Sep 01, 2015: Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I 51

Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01 52

May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting 53

Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs 54

Nov 21, 2014: Final Analysis of the Phase II Clinical Study on Elafin in coronary artery bypass surgery completed 54

May 20, 2014: $ 4.8 Million Funding for Proteo's Advanced Orphan Drug Development 55

Nov 08, 2013: Proteo, Inc. / Proteo Biotech AG: Patient Recruitment and Treatment in Elafin CABG Phase II Clinical Trial Completed 55

Mar 20, 2013: Proteo's Elafin Obtains FDA Orphan Drug Designation For Prevention Of Inflammatory Complications Of Transthoracic Esophagectomy 56

Jan 10, 2013: Proteo's Elafin Receives FDA Orphan Drug Designation For Treatment Of Pulmonary Arterial Hypertension 56

Dec 11, 2012: Proteo Announces Patient Recruitment For EMPIRE Study Of Elafin Surpassed Expectations 57

Jun 27, 2012: Researchers Provide Further Rationale For Proteo's Elafin Treatment In Newborn Infants 58

Jun 22, 2012: Proteo Provides Update On Phase II Study Of Elafin In Coronary Bypass Surgery 58

Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 59

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 22

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by AstraZeneca Plc, H2 2016 24

Pipeline by Cantex Pharmaceuticals Inc, H2 2016 25

Pipeline by Chiesi Farmaceutici SpA, H2 2016 26

Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 27

Pipeline by Polyphor Ltd, H2 2016 28

Pipeline by Proteo Inc, H2 2016 29

Dormant Projects, H2 2016 46

Dormant Projects (Contd..1), H2 2016 47

Dormant Projects (Contd..2), H2 2016 48

Dormant Projects (Contd..3), H2 2016 49

Discontinued Products, H2 2016 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AstraZeneca Plc, Cantex Pharmaceuticals Inc, Chiesi Farmaceutici SpA, Kyorin Pharmaceutical Co Ltd, Polyphor Ltd, Proteo Inc

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) Therapeutic Products under Development, Key Players in Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) Therapeutics, Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) Pipeline Overview, Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) Pipeline, Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) Pipeline Assessment

select a license

Single User License
USD 3500 INR 226730
Site License
USD 7000 INR 453460
Corporate User License
USD 10500 INR 680190

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com